It was reported that on (b)(6) 2022, an 8 x 30mm xact stent was successfully implanted to treat the 80% stenosed lesion in the tortuous right internal carotid artery.The patient was discharged.However, on (b)(6) 2022, the patient was readmitted to the emergency department with symptoms of a stroke.The stent was no longer patent as there was thrombus from the right common carotid artery to the internal carotid artery.Lab tests were performed and the patient was treated with plavix.However, the patient did not respond to the medication and the thrombus remained untreated.The patient was referred to hospice.No additional information was given.
|
The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of thrombosis (thromboembolic episodes) and cerebral hemorrhage (cerebrovascular accident) are listed in the xact carotid stent system information for prescribers as adverse events potentially associated with carotid stents and embolic protection systems.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.However, the treatments appear to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|